Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the reversibility of the elevation of serum creatinine levels in patients with diabetes after 5 years of continuous on-trial fenofibrate therapy. RESEARCH DESIGN AND METHODS: An on-drug/off-drug ancillary study to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial to investigate posttrial changes in serum creatinine and cystatin C. Eligible participants were recruited into a prospective, nested, three-group study based on retrospective on-trial serum creatinine levels: fenofibrate case subjects (n = 321, ≥20% increase after 3 months of therapy); fenofibrate control subjects (n = 175, ≤2% increase); and placebo control subjects (n = 565). Serum creatinine and cystatin C were measured at trial end and 6–8 weeks after discontinuation of trial therapy. RESULTS: At trial end, case subjects had the highest adjusted serum creatinine (± SE) mg/dL (1.11 ± 0.02) and the lowest adjusted estimated glomerular filtration rate (eGFR) (± SE) mL/min/1.73 m2 (68.4 ± 1.0) versus control subjects (1.01 ± 0.02; 74.8 ± 1.3) and placebo subjects (0.98 ± 0.01; 77.8 ± 0.7). After 51 days off-drug, serum creatinine in case subjects was still higher (0.97 ± 0.02) and eGFR still lower (77.8 ± 1.0) than control subjects (0.90 ± 0.02; 81.8 ± 1.3) but not different from placebo subjects (0.99 ± 0.01; 76.6 ± 0.7). Changes in serum cystatin C recapitulated the serum creatinine changes. CONCLUSIONS: Participants with significant initial on-trial increases in serum creatinine (≥20%) returned to the same level of renal function as participants receiving placebo while participants who had ≤2% increase in serum creatinine had net preservation of renal function compared with the same unselected placebo reference group. The fenofibrate-associated on-trial increases in serum creatinine were reversible, and the reversal was complete after 51 days off-drug. The similarity of the cystatin C results suggests that the mechanism of this change is not specific for serum creatinine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is a known effect of PPAR-α agonists.[27][28][29]”
From A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis (2018) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These potential explanations have supported the view that the drug-induced elevations in serum creatinine does not reflect a true deterioration of renal function”
From Effects of Fibrates in Kidney Disease (2012) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, we confirm prior reports that demonstrated the association of fenofibrate use with preservation of kidney function in patients with diabetes.12, 13”
From Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similarly, reversibility in acute increases in creatinine has been described amongst participants in the ACCORD study (50).”
From Effects of Fibrates in Kidney Disease (2012) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“We used the month 4 eGFR for our baseline eGFR given the increase in creatinine seen with fibrates after initiating therapy.13”
From Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes (2019) · cites this paper as [13]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Stevens, L. A., Coresh, J., Schmid, C. H., Feldman, H. I., Froissart, M., Kusek, J., Rossert, J., Van Lente, F., Bruce, R. D., Zhang, Y. (., et al. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.11.018 · Cited by 1,037
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods
Buse, J. B. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.003 · Cited by 661
Self-citationon behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371
Ansquer, J.-C., Foucher, C., Rattier, S., Taskinen, M.-R., & Steiner, G. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.11.004 · Cited by 264
Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine
Hottelart, C., El Esper, N., Rose, F., Achard, J.-M., & Fournier, A. (2002) · Nephron · doi:10.1159/000064083 · Cited by 186
Cited by
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319
Self-citationDiabetic nephropathy: diagnosis and treatment
Fineberg, D., Jandeleit-Dahm, K. A. M., & Cooper, M. E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.184 · Cited by 295
Lincoff, A. M., Tardif, J.-C., Schwartz, G. G., Nicholls, S. J., Rydén, L., Neal, B., Malmberg, K., Wedel, H., Buse, J. B., Henry, R. R., et al. (2014) · JAMA · doi:10.1001/jama.2014.3321 · Cited by 231
Self-citationde Vries, E., Bolier, R., Goet, J., Parés, A., Verbeek, J., de Vree, M., Drenth, J., van Erpecum, K., van Nieuwkerk, K., van der Heide, F., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.001 · Cited by 224
Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30246-7 · Cited by 191
Ishibashi, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Yamashita, S. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.10.006 · Cited by 184
Effects of Fibrates in Kidney Disease
Jun, M., Zhu, B., Tonelli, M., Jardine, M. J., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., & Perkovic, V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.049 · Cited by 189
Elam, M. B., Ginsberg, H. N., Lovato, L. C., Corson, M., Largay, J., Leiter, L. A., Lopez, C., O’Connor, P. J., Sweeney, M. E., Weiss, D., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4828 · Cited by 185
Self-citationResidual macrovascular risk in 2013: what have we learned?
(R3i), F. T. R. R. R. I., Fruchart, J.-C., Davignon, J., Hermans, M. P., Al-Rubeaan, K., Amarenco, P., Assmann, G., Barter, P., Betteridge, J., Bruckert, E., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-26 · Cited by 172
Self-citationPrimary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159
Fruchart, J.-C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0602-y · Cited by 141
“001) [57], consistent with previous findings from both the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and ACCORD studies [64, 65].”
ResultFruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140
Self-citationAverna, M., Banach, M., Bruckert, E., Drexel, H., Farnier, M., Gaita, D., Magni, P., März, W., Masana, L., Mello e Silva, A., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.039 · Cited by 137
Noonan, J. E., Jenkins, A. J., Ma, J.-X., Keech, A. C., Wang, J. J., & Lamoureux, E. L. (2013) · Diabetes · doi:10.2337/db13-0800 · Cited by 120
Nadkarni, G. N., Rao, V., Ismail-Beigi, F., Fonseca, V. A., Shah, S. V., Simonson, M. S., Cantley, L., Devarajan, P., Parikh, C. R., & Coca, S. G. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12051115 · Cited by 114
Glucose targets for preventing diabetic kidney disease and its progression
Ruospo, M., Saglimbene, V. M., Palmer, S. C., De Cosmo, S., Pacilli, A., Lamacchia, O., Cignarelli, M., Fioretto, P., Vecchio, M., Craig, J. C., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010137.pub2 · Cited by 111
The key role of altered tubule cell lipid metabolism in kidney disease development
Lee, L. E., Doke, T., Mukhi, D., & Suszták, K. (2024) · Kidney International · doi:10.1016/j.kint.2024.02.025 · Cited by 126
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 100
Ferrari, R., Aguiar, C., Alegria, E., Bonadonna, R. C., Cosentino, F., Elisaf, M., Farnier, M., Ferrières, J., Filardi, P. P., Hancu, N., et al. (2016) · European Heart Journal Supplements · doi:10.1093/eurheartj/suw009 · Cited by 97
Dyslipidemia in diabetic nephropathy
Kawanami, D., Matoba, K., & Utsunomiya, K. (2016) · Renal Replacement Therapy · doi:10.1186/s41100-016-0028-0 · Cited by 109
Effect of Fenofibrate on Progression of Diabetic Retinopathy
Preiss, D., Logue, J., Sammons, E. L., Zayed, M., Emberson, J., Wade, R. L., Wallendszus, K., Stevens, W., Cretney, R., Harding, S. P., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2400179 · Cited by 117
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 103
The Contribution of Lipotoxicity to Diabetic Kidney Disease
Schelling, J. R. (2022) · Cells · doi:10.3390/cells11203236 · Cited by 98
Aguíar, C., Alegría, E., Bonadonna, R. C., Catapano, A. L., Cosentino, F., Elisaf, M., Farnier, M., Ferrières, J., Filardi, P. P., Hâncu, N., et al. (2015) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(15)30001-5 · Cited by 90
Wissing, K. M., & Pipeleers, L. (2014) · Transplantation Reviews · doi:10.1016/j.trre.2013.12.004 · Cited by 89
Lipid mediators in diabetic nephropathy
Srivastava, S. P., Shi, S., Koya, D., & Kanasaki, K. (2014) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-7-12 · Cited by 67
Fenofibrate and Diabetic Retinopathy
Knickelbein, J. E., Abbott, A. B., & Chew, E. Y. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0786-7 · Cited by 72
Fenofibrate and the kidney: an overview
Kostapanos, M. S., Florentin, M., & Elisaf, M. S. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12068 · Cited by 65
Frazier, R., Mehta, R., Cai, X., Lee, J., Napoli, S., Craven, T., Tuazon, J., Safdi, A., Scialla, J., Susztak, K., et al. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2018.09.006 · Cited by 63
“Emerging data from clinical trials of glucagon-like peptide 1 agonists and sodium– glucose cotransporter 2 inhibitors suggest that use of these new classes of hypoglycemic medications may improve kidney outcomes in patients with type 2 diabetes.4–6 Despite exciting advances, the prevalence of diabetic kidney disease r…”
BackgroundMethodResultInfluentialSelf-citationHegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
“on fenofibrate returned to baseline levels with cessation of treatment.(69) There is no evidence supporting the use of fenofibrate in nondyslipidemic people and in women without dyslipidemia, fenofibrate may increase risk of CVD”
BackgroundSelf-citationDavidson, M. H., Rosenson, R. S., Maki, K. C., Nicholls, S. J., Ballantyne, C. M., Mazzone, T., Carlson, D. M., Williams, L. A., Kelly, M. T., Camp, H. S., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.302926 · Cited by 64
Use of nephrotoxic medications in adults with chronic kidney disease in Swedish and US routine care
Bosi, A., Xu, Y., Gasparini, A., Wettermark, B., Barany, P. F., Bellocco, R., Inker, L. A., Chang, A. R., McAdams‐DeMarco, M., Grams, M. E., et al. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab210 · Cited by 66
Fenofibrate-associated nephrotoxicity: A review of current evidence
Attridge, R. L., Frei, C. R., Ryan, L., Koeller, J., & Linn, W. D. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120131 · Cited by 57
Cicero, A. F. G., Pontremoli, R., Fogacci, F., Viazzi, F. C., & Borghi, C. (2020) · Drug Safety · doi:10.1007/s40264-020-00931-6 · Cited by 55
Ginsberg, H. N., Hounslow, N. J., Senko, Y., Suganami, H., Bogdanski, P., Ceska, R., Kalina, A., Libis, R. A., Supryadkina, T. V., & Hovingh, G. K. (2022) · Diabetes Care · doi:10.2337/dc21-1288 · Cited by 48
Self-citationMottl, A. K., Buse, J. B., Ismail-Beigi, F., Sigal, R. J., Pedley, C. F., Papademetriou, V., Simmons, D. L., Katz, L., Mychaleckyj, J. C., & Craven, T. E. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06200518 · Cited by 48
Self-citationFenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD
Ferreira, J. P., Vasques‐Nóvoa, F., Ferrão, D., Saraiva, F. A., Falcão‐Pires, I., Neves, J. S., Sharma, A., Rossignol, P., Zannad, F. M., & Leite-Moreira, A. F. (2022) · Diabetes Care · doi:10.2337/dc21-1977 · Cited by 49
Lincoff, A. M., Tardif, J., Neal, B. C., Nicholls, S. J., Rydén, L., Schwartz, G. G., Malmberg, K., Buse, J. B., Henry, R. R., Wedel, H., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.013 · Cited by 46
Self-citationStreja, E., Kovesdy, C. P., Streja, D. A., Moradi, H., Kalantar‐Zadeh, K., & Kashyap, M. L. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.11.033 · Cited by 39
Montaño‐Loza, A. J., & Corpechot, C. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.062 · Cited by 44
Epidemiological characteristics of diabetic kidney disease in Taiwan
Wang, J., Yen, F., Lin, K., Shin, S., Hsu, Y., & Hsu, C. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13668 · Cited by 41
Effect of Fenofibrate Medication on Renal Function
Kim, S., Ko, K., Park, S., Lee, D. R., & Lee, J. (2017) · Korean Journal of Family Medicine · doi:10.4082/kjfm.2017.38.4.192 · Cited by 40
Dutta, D., Bhattacharya, S., Surana, V., Aggarwal, S., Singla, R., Khandelwal, D., & Sharma, M. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.08.039 · Cited by 34
Duan, W., Ou, X., Wang, X., Wang, Y., Zhao, X., Wang, Q., Wu, X., Zhang, W., Ma, H., You, H., et al. (2018) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2018.5533/2018 · Cited by 30
Fibroblast Growth Factor 23 and Incident CKD in Type 2 Diabetes
Isakova, T., Craven, T. E., Lee, J. J., Scialla, J. J., Xie, H., WAHL, P. W., Marcovina, S. M., Byington, R. P., & Wolf, M. S. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06190614 · Cited by 28
Self-citationKawasaki, M., Kambe, A., Yamamoto, Y., Arulmozhiraja, S., Ito, S., Nakagawa, Y., Tokiwa, H., Nakano, S., & Shimano, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010361 · Cited by 31
Diabetic kidney disease and risk of incident stroke among adults with type 2 diabetes
Kazé, A. D., Jaar, B. G., Fonarow, G. C., & Echouffo-Tcheugui, J. B. (2022) · BMC Medicine · doi:10.1186/s12916-022-02317-0 · Cited by 29
Fenofibrate-induced renal dysfunction, yes or no?
Nematbakhsh, M., Emami, F., Hariri, A., & Matinfar, M. (2020) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_772_19 · Cited by 25
Ruilope, L. M., Hanefeld, M., Lincoff, A. M., Viberti, G. C., Reigner, S. M., Mudie, N. Y., Kirk, D. A. W., Malmberg, K., & Herz, M. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-180 · Cited by 27
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)
Ali, M. M., Parveen, S., Williams, V. R., Dons, R. F., & Uwaifo, G. I. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100341 · Cited by 41
Fatty kidney: A possible future for chronic kidney disease research
Kanbay, M., Çöpür, S., Demiray, A., Sag, A. A., Covic, A. C., Ortíz, A., & Tuttle, K. R. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13748 · Cited by 26
Hughes, E. P., Wang, X. X., Sabol, L., Barton, K., Hegde, S., Myakala, K., Krawczyk, E., Rosenberg, A. Z., & Levi, M. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00110.2025 · Cited by 29
Sugimoto, R., Iwasa, M., Eguchi, A., Tamai, Y., Shigefuku, R., Fujiwara, N., Tanaka, H., Kobayashi, Y., Ikoma, J., Kaito, M., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1073025 · Cited by 27
Safety considerations with fenofibrate/simvastatin combination
Filippatos, T. D., & Elisaf, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1056778 · Cited by 24
The Role of Fibrates in Primary Biliary Cholangitis
Corpechot, C. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00455-3 · Cited by 25
Plasma endostatin predicts kidney outcomes in patients with type 2 diabetes
Chauhan, K., Verghese, D. A., Rao, V. S., Chan, L., Parikh, C. R., Coca, S. G., & Nadkarni, G. N. (2018) · Kidney International · doi:10.1016/j.kint.2018.09.019 · Cited by 22
Novel Therapies for Kidney Disease in People With Diabetes
Khurana, N., James, S., Coughlan, M. T., MacIsaac, R. J., & Ekinci, E. I. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab639 · Cited by 23
Lipids: A Major Culprit in Diabetic Nephropathy
Beniwal, A., Jain, J. C., & Jain, A. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998259273231101052549 · Cited by 23
Isakova, T., Craven, T. E., Scialla, J. J., Nickolas, T. L., Schnall, A. M., Barzilay, J. I., & Schwartz, A. V. (2015) · Bone · doi:10.1016/j.bone.2015.04.037 · Cited by 23
Self-citationTang, Y., Ang, L. P., Jaiswal, M., Dillon, B. R., Esfandiari, N. H., Shah, H., Spino, C., Plunkett, C., Perkins, B. A., Pop‐Busui, R., et al. (2023) · Diabetes · doi:10.2337/db23-0247 · Cited by 25
Yen, C., Fan, P., Lin, M., Lee, C., Tu, K., Chen, C., Hsiao, C.-C., Hsu, H., Tian, Y., & Chang, C. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab137 · Cited by 20
Impact of fenofibrate therapy on serum uric acid concentrations: a review and meta-analysis
Zhang, J., Ji, X., Dong, Z., Lü, J., Zhao, Y., Li, R., Li, C., & Chen, Y. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej20-0808 · Cited by 22
Koopal, C., Marais, A. D., Westerink, J., van der Graaf, Y., & Visseren, F. L. J. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m076901 · Cited by 21
Liu, Q., Guo, S., Tong, Y., Li, Q., Baoxiang, Z., Wang, J., Wang, Y., Gao, W., & Zou, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70220 · Cited by 21
Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?
Simó, R., Simó‐Servat, O., & Hernández, C. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0599-0 · Cited by 18
Mark, P. B., Winocour, P. H., & Day, C. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.125 · Cited by 18
Fruchart, J., Hermans, M. P., & Fruchart‐Najib, J. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00860-w · Cited by 19
Lessons from PROMINENT and prospects for pemafibrate
Fruchart, J.-C., Fruchart-Najib, J., Yamashita, S., Libby, P., Yokote, K., Kodama, T., Tomita, Y., Ridker, P. M., Hermans, M. P., & Zambon, A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02305-z · Cited by 16
“Similar findings have been reported with fenofibrate in the ACCORD and FIELD trials [12, 18], although another study suggested that long-term fenofibrate may delay impairment in renal function in T2DM patients [17].”
BackgroundResultCzupryniak, L., Joshi, S., Gogtay, J. A., & Lopez, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1195811 · Cited by 19
SPPARM alpha: the Lazarus effect
Fruchart, J., & Santos, R. D. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000640 · Cited by 19
Ericsson, A., Tonelius, P., Lal, M., Sabirsh, A., Böttcher, G., William‐Olsson, L., Strömstedt, M., Johansson, C., Hyberg, G., Tapani, S., et al. (2017) · Physiological Reports · doi:10.14814/phy2.13186 · Cited by 16
Fenofibrate and risk of end‐stage renal disease: A nationwide cohort study
Hyun, Y. Y., Kim, K., Hong, S., Han, K., & Park, C. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15815 · Cited by 18
Papademetriou, V., Lovato, L., Tsioufis, C. P., Cushman, W. C., Applegate, W. B., Mottle, A., Punthakee, Z., Nylén, E., Doumas, M. N., & for the ACCORD Study Group (2016) · American Journal of Nephrology · doi:10.1159/000453626 · Cited by 16
The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats
Guo, C., Xue, S., Zheng, X., Lu, Y., Zhao, D., Chen, X., & Li, N. (2017) · Xenobiotica · doi:10.1080/00498254.2017.1306760 · Cited by 15
Foucher, C., Aubonnet, P., Reichert, P., Berli, M. A., Schaeffer, A., Vargas, C. G. C., Lochocka, A., Belenky, D., Koch, H., & the Cholib study Investigators (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12148 · Cited by 15
Saito, T., Yamada, E., Okada, S., Shimoda, Y., Tagaya, Y., Hashimoto, K., Satoh, T., Mori, M., Okada, J., Pessin, J. E., et al. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0330 · Cited by 12
Dislipidemia aterogénica y riesgo residual. Estado de la cuestión en 2014
Núñez-Cortés, J. M., Pedro‐Botet, J., & Pintó, X. (2014) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2014.09.004 · Cited by 20
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Regemorter, E. V., Jadoul, M., & Gillion, V. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2216470 · Cited by 12
Weinstein, D. L., Williams, L. A., Carlson, D. M., Kelly, M. T., Burns, K. M., Setze, C. M., Lele, A., & Stolzenbach, J. C. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.06.013 · Cited by 13
Sahebkar, A., Simental-Mendía, L. E., Pirro, M., Montecucco, F., Carbone, F., Banach, M., Barreto, G. E., & Butler, A. E. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1495338 · Cited by 9
“Selected studies enrolled subjects with dyslipidemia [28,29,31,32,34,35], type 2 diabetes [30,33], and healthy subjects [27].”
BackgroundIwasa, M., Sugimoto, R., Eguchi, A., Tamai, Y., Shigefuku, R., Fujiwara, N., Tanaka, H., Kobayashi, Y., Ikoma, J., Kaito, M., et al. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002766 · Cited by 10
Effects of fenofibrate therapy on renal function in primary gout patients
Li, X., Sun, W., Lü, J., He, Y., Chen, Y., Ren, W., Cui, L., Liu, Z., Wang, C., Wang, X., et al. (2021) · Rheumatology · doi:10.1093/rheumatology/keab231 · Cited by 9
Yanai, H., Katsuyama, H., & Hakoshima, M. (2021) · Cardiology Research · doi:10.14740/cr1333 · Cited by 9
Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms
Amioka, N., Miyoshi, T., Yonezawa, T., Kondo, M., Akagi, S., Yoshida, M., Saito, Y., Nakamura, K., & Ito, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.904215 · Cited by 10
Complicaciones microvasculares de la diabetes
Pérez‐Pevida, B., Llavero, M., Gargallo, J., & Escalada, J. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.09.003 · Cited by 15
Chauhan, K., Nadkarni, G. N., Debnath, N., Chan, L., Saha, A., Garg, A. X., Parikh, C. R., & Coca, S. G. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00370119 · Cited by 10
de Expertos, G. D. T. D. D. A. D. L. S. E. D. A. Y. G. E. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.12.001 · Cited by 13
Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study
Iwasaki, M., Suzuki, H., Umezawa, Y., Koshida, T., Saito, M., Fukuda, H., Takahara, H., Matsuzaki, K., & Suzuki, Y. (2023) · Medicine · doi:10.1097/md.0000000000032818 · Cited by 12
Hermans, M. P. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000413 · Cited by 8
Kim, J. Y., Kim, N. H., Lee, J. Y., Kim, D., & Kim, S. G. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf053 · Cited by 10
Beyond lipids: fenofibrate in diabetic retinopathy and nephropathy
Liu, M., Lim, S. T., Song, W., Coffman, T. M., & Wang, X. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.07.014 · Cited by 14
Aterogénica, P. E. D. E. V. E. D. G. D. T. S. D. (2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.12.001 · Cited by 11
Júnior, C. R. B., Bano, A., Tang, Y., Sun, X., Abate, A., Hall, E., Mitri, J., Morieri, M. L., Shah, H., & Doria, A. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01869-6 · Cited by 12
Fenofibrate and Impaired Taste Perception in Type 2 Diabetes
Davis, T. M. E. (2020) · American Journal of Case Reports · doi:10.12659/ajcr.927647 · Cited by 6
Mae, Y., Takata, T., Taniguchi, S., Fujino, Y., Kageyama, K., Hanada, H., Iyama, T., Sugihara, T., & Isomoto, H. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.11.029 · Cited by 6
Management of Presumed Acute Kidney Injury during Hypertensive Therapy: Stay Calm and Carry on?
Chen, T. K., & Parikh, C. R. (2020) · American Journal of Nephrology · doi:10.1159/000505447 · Cited by 7
Chan, Y., Chao, T., Chen, S., Kao, Y., Huang, C.-Y., & Chu, P. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000159 · Cited by 7
Fibrates: A Possible Treatment Option for Patients with Abdominal Aortic Aneurysm?
Amioka, N., & Miyoshi, T. (2022) · Biomolecules · doi:10.3390/biom12010074 · Cited by 6
Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?
Fruchart, J., Santos, R. D., Yamashita, S., Libby, P., Fruchart, J., Santos, R. D., Yamashita, S., Aikawa, M., Libby, P., Plutzky, J., et al. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.034 · Cited by 6
Self-citation
Metadata
- Authors
- Mychaleckyj, J. C., Craven, T., Nayak, U., Buse, J., Crouse, J. R., Elam, M., Kirchner, K., Lorber, D., Marcovina, S., Sivitz, W., Sperl-Hillen, J., Bonds, D. E., & Ginsberg, H. N.
- Affiliations
- University of Virginia (US)
- Wake Forest University Health Sciences (US)
- University of North Carolina at Chapel Hill (US)
- Memphis VA Medical Center (US)
- G.V. (Sonny) Montgomery VA Medical Center (US)
- New York Hospital Queens (US)
- University of Washington (US)
- University of Iowa (US)
- Health Partners Research Foundation, Minneapolis, Minnesota
- National Institutes of Health (US)
- Columbia University (US)
- Corresponding author
- Mychaleckyj, Josyf C.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-04-11
- Volume
- 35
- Issue
- 5
- Pages
- 1008-1014
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3329840
- OpenAlex
- W2022162088
- Cited by
- 149
- References
- 20
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 8 · 2023: 12 · 2022: 9 · 2021: 8 · 2020: 9 · 2019: 7 · 2018: 10 · 2017: 13 · 2016: 13 · 2015: 12 · 2014: 13 · 2013: 11 · 2012: 3
- FWCI
- 9.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Hispana (submittedVersion)
- UNC Libraries
- Funders
- American Diabetes Association
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Osiris Therapeutics
- MannKind Corporation
- Halozyme
- Omron Healthcare
- Bayer HealthCare
- Novo Nordisk
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- Centers for Disease Control and Prevention
- National Institute on Aging
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- National Eye Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- fenofibrate, serum creatinine, cystatin C, estimated glomerular filtration rate, type 2 diabetes, drug discontinuation, renal function recovery, lipid-lowering therapy, placebo comparison, cardiovascular risk in diabetes
- MeSH terms
- Aged, Hypolipidemic Agents, Creatinine, Glomerular Filtration Rate, Humans, Middle Aged, Fenofibrate, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.